Cargando…

The Need for Precision Therapies as Determined by Genetic Signature for Cystic Fibrosis

Detalles Bibliográficos
Autor principal:	Zahir, Farah R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708496/ https://www.ncbi.nlm.nih.gov/pubmed/34945826 http://dx.doi.org/10.3390/jpm11121353

Ejemplares similares

Cystic fibrosis-related diabetes: The unmet need
por: Pozo, Leonardo, et al.
Publicado: (2020)

Unraveling the CFTR Function–Phenotype Connection for Precision Treatment in Cystic Fibrosis
por: Zemanick, Edith T., et al.
Publicado: (2019)

Steps toward Cell Therapy for Cystic Fibrosis
por: Koh, Kyung Duk, et al.
Publicado: (2020)

Newborn Screening for Cystic Fibrosis: Over the Hump, Still Need to Fine-Tune It
por: Castellani, Carlo
Publicado: (2020)

TMEM16A Potentiators: Is There a Need for New Modulators in Cystic Fibrosis?
por: Kim, Michael D., et al.
Publicado: (2020)

Editorial on the Paper “The Epidemiology and Genetics of Hyperuricemia and Gout across Major Racial Groups: A Literature Review and Population Genetics Secondary Database Analysis” by Butler, Alghoubayshi and Roman
por: Zahir, Farah R.
Publicado: (2022)

The Future of Highly Effective Modulator Therapy in Cystic Fibrosis
por: Daines, Cori L., et al.
Publicado: (2021)

Cystic fibrosis revisited
por: Kulkarni, H, et al.
Publicado: (2019)

Gene therapy for cystic fibrosis: new tools for precision medicine
por: Lee, Jin-A, et al.
Publicado: (2021)

Early Antibiotics in Cystic Fibrosis: Lessons from the Cystic Fibrosis Pig Model
por: Lu, Shiping, et al.
Publicado: (2021)

Cystic Fibrosis Screen Positive, Inconclusive Diagnosis Genotypes in the Cystic Fibrosis Registry
por: Thompson, Cassandra, et al.
Publicado: (2023)

Microbial Metabolites in Cystic Fibrosis: A Target for Future Therapy?
por: Widder, Stefanie, et al.
Publicado: (2019)

Combination Therapy with Lumacaftor–Ivacaftor in Cystic Fibrosis. Keeping It Real
por: Sala, Marc A., et al.
Publicado: (2020)

Precision noninvasive brain stimulation: is it precise? Is it needed?
por: Borrione, Lucas, et al.
Publicado: (2019)

Clinical Advances in Cystic Fibrosis
por: Imperlini, Esther, et al.
Publicado: (2022)

Cystic Fibrosis: “Ionocyte Modulators”?
por: Shah, Viral S., et al.
Publicado: (2023)

The treatment burden of cystic fibrosis: a day-to-day experience with treatment as someone with cystic fibrosis
por: Maetz, Jessica, et al.
Publicado: (2021)

Azithromycin and Tobramycin Therapy in Cystic Fibrosis Pulmonary Exacerbations: Less Is More?
por: Thornton, Christina, et al.
Publicado: (2021)

Personalized or Precision Medicine? The Example of Cystic Fibrosis
por: Marson, Fernando A. L., et al.
Publicado: (2017)

A New Era for Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator Modulator Trials in Infants
por: Wainwright, Claire E.
Publicado: (2022)

Who Modifies the Modifiers: A High-Resolution View of the Genetic Modifiers of Cystic Fibrosis
por: Kalra, Sean, et al.
Publicado: (2023)

Cystic fibrosis in Brazil: achievements in survival
por: Vendrusculo, Fernanda Maria, et al.
Publicado: (2021)

The Impact of COVID-19 in Cystic Fibrosis
por: Flume, Patrick A., et al.
Publicado: (2022)

Evidence for Early Cystic Fibrosis Transmembrane Conductance Regulator Modulator Treatment for Children with Cystic Fibrosis Keeps Growing
por: Hoppe, Jordana E., et al.
Publicado: (2022)

Evolving Nutritional Needs in Cystic Fibrosis
por: Frantzen, Theresa, et al.
Publicado: (2023)

Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy
por: Tewkesbury, Daniel H., et al.
Publicado: (2021)

Needed in Psychology: Theoretical Precision
por: Valsiner, Jaan
Publicado: (2018)

An inflammatory Signature of Glucose Impairment in Cystic Fibrosis
por: Montemari, Anna Lisa, et al.
Publicado: (2022)

Where Is the Cystic Fibrosis Transmembrane Conductance Regulator?
por: Barbry, Pascal, et al.
Publicado: (2021)

Dornase alpha use in patients with cystic fibrosis
por: Marostica, Paulo José C.
Publicado: (2013)

New Developments in Cystic Fibrosis Airway Inflammation
por: Palaniyar, Nades, et al.
Publicado: (2015)

Ciprofloxacin dry powder inhaler in cystic fibrosis
por: Elborn, J Stuart
Publicado: (2016)

Comparing cystic fibrosis outcomes across the pond
por: Taylor-Robinson, David C, et al.
Publicado: (2015)

Preclinical Modeling for Therapeutic Development in Cystic Fibrosis
por: Bonfield, Tracey L.
Publicado: (2020)

Cystic Fibrosis Inflammation: Hyperinflammatory, Hypoinflammatory, or Both?
por: Murphy, Sean V., et al.
Publicado: (2019)

How Should the Effects of CFTR Modulator Therapy on Cystic Fibrosis Lung Disease Be Monitored?
por: Ben-Meir, Elad, et al.
Publicado: (2022)

Precision medicine: In need of guidance and surveillance
por: Lin, Jian-Zhen, et al.
Publicado: (2017)

Cystic fibrosis autoantibody signatures associate with Staphylococcus aureus lung infection or cystic fibrosis-related diabetes
por: Yadav, Ruchi, et al.
Publicado: (2023)

Nutrition in Cystic Fibrosis: as important as the management of pulmonary disease
por: Adde, Fabíola Villac
Publicado: (2015)

Airway Inflammatory/Immune Responses in COPD and Cystic Fibrosis
por: De Rose, Virginia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_06qcfm3lr8p6thsd6j5dbcd9uj